SCRIP: World Pharmaceutical News

November 05, 2004

Avestha Gengraine and CCBR form joint venture in osteoporosis

The Indian biotechnology and bioinformatics company, Avestha Gengraine Technologies, has entered into a joint venture with the Denmark-based CRO, the Centre for Clinical & Basic Research (CCBR), and its subsidiary, Nordic Biosciences, to work on osteoporosis and osteoarthritis. The alliance will cover the diagnosis, treatment and prevention of osteoporosis and osteoarthritis. The partners expect to put together a comprehensive platform to develop novel technologies that integrate the diagnosis and treatment of osteoporosis. Avestha Gengraine also expects to link its competences in preclinical research with CCBR's experience in clinical research in osteoporosis to develop nutritional bioactive ingredients and new drug leads. Both companies plan to jointly market these products globally.